Email us connect@hepdconnect.org
Welcome to Hepatitis Delta Connect!
A dedicated program of the Hepatitis B Foundation to increase awareness about hepatitis delta - a serious virus that coinfects hepatitis B patients - and to promote screening and testing, and provide information and support for those affected.
Clinical Trial Finder - Find A Clinical Trial Near You!
Watch our latest webinar!
We would love to hear from you! Complete the survey to sign up!
Take our brief survey & sign up to receive updates on clinical trials, info about hepatitis delta monitoring, management & care + more! Sign up today!
We've educated 13,000 people in 111 countries!
News & Updates
January 2021 Blog Post: Eiger Presents Clinical Trial Results at The Liver Meeting Digital Experience™ 2020
September 2020 Blog Post: New Hepatitis Delta Treatment Approved by European Commission
May 2020 Blog Post: Does Hepatitis Delta Increase My Risk for Liver Cancer?
View our recent webinar, Hepatitis Delta Treatment Endpoints: How Do We Measure Success in the Era of Emerging Therapies? recording here.
Phase 3 clinical trials are now open for hepatitis delta, click here for more information.
08/24/2021: The Highly Complementary Model of Hepatitis D and Hepatitis B, Described by Scientists, Can Broadly Cover the HDV Replication Cycle
07/28/2021: Hepatitis D: Neglected Disease in the Race to Eliminate Viral Hepatitis by 2030
07/27/2021: Risk of Hepatocellular Carcinoma in Hepatitis B & D Virus Co-Infected Patients: A Systematic Review and Meta-Analysis of Longitudinal Studies
07/12/2021: Significant Disparities in the International Incidence of Hepatitis Delta Virus
06/25/2021: Gilead Preps Filing for Hepatitis D Therapy Hepcludex in US
06/24/2021: Treatment With Hepcludex® (Bulevirtide) Was Shown to Achieve Significant Response in Chronic Hepatitis Delta Virus After 24 Weeks
04/01/2021: Hepatitis Delta Infection Among Persons with HIV in Europe
11/30/20: New Insights into Hepatitis D Virus Persistence: The Role of Interferon Response and Implications for Upcoming Novel Therapies
11/17/20: Eiger Announces Positive Peginterferon Lambda-Lonafarnib Combination End-of-Study Results from Phase 2 LIFT HDV Study at the Liver Meeting Digital Experience 2020
11/16/20: Eiger Announces Case Studies Demonstrating Regression of Liver Fibrosis Following 48 Weeks of Therapy with Peginterferon Lambda in Patients with Chronic HDV Infection at the Liver Meeting Digital Experience 2020
10/7/20: Risk Factors for Delta Hepatitis in a North American Cohort: Who Should Be Screened?
9/17/20: Hepcludex Launched in Germany, France, and Austria
8/31/20: End of Treatment Results Presented for Lambda-Interferon + Lonafarnib Combination Phase 2 Study
Get Connected
